BofA warns Fed risks policy mistake with early rate cuts
On Monday, Serina Therapeutics (NYSE:SER) received a new Buy rating from Jones Trading, accompanied by a price target set at $11.00, representing significant upside from its current trading price of $4.78. The micro-cap company, valued at $47.58 million, which focuses on drug delivery and is on the cusp of entering clinical stages, was brought to the public markets through a reverse merger with AgeX Therapeutics in March 2024. InvestingPro analysis indicates the company is currently trading above its Fair Value, joining other overvalued biotechnology stocks tracked on the Most Overvalued list.
The initiation of coverage by Jones Trading follows the sale of AgeX’s legacy assets and debt, which were divested to the UniverXome Bioengineering subsidiary in December 2024. This move has seemingly paved the way for Serina Therapeutics to progress with its strategic plans, though InvestingPro data reveals the company faces financial challenges with a current ratio of 0.4, indicating short-term obligations exceed liquid assets.
Serina Therapeutics is now positioned to advance its drug delivery technology, which is expected to be a significant step for the company as it transitions to clinical trials. The establishment of a Buy rating by Jones Trading reflects a positive outlook on the company’s future performance and potential growth in the biotech industry.
The price target of $11.00 suggests a level of confidence in the company’s value proposition and its ability to achieve its scientific and financial goals. This target is indicative of the potential that Jones Trading sees in Serina Therapeutics’ stock.
Investors may view the new coverage and price target as a sign of Serina Therapeutics’ promising position in the biotech market. As the company prepares to enter clinical stages, the Buy rating may attract attention to its stock as a potential opportunity within the sector.
In other recent news, Serina Therapeutics has completed the second tranche of its $10 million equity financing, securing an additional $5 million from JuvVentures (UK) Limited. This funding will support the advancement of SER-252, Serina’s investigational therapy for advanced Parkinson’s disease, into Phase 1 clinical trials expected in the latter half of 2025. The transaction involved issuing 500,000 shares of common stock at $10 per share, which represents a 113% premium over the January 31, 2025 closing price. JuvVentures also received warrants for 755,728 shares at an $18.00 exercise price. CEO Steve Ledger emphasized the importance of this financing in strengthening Serina’s cash position as they move forward with SER-252. The therapy utilizes Serina’s proprietary POZ Platform™ and Enable Injections’ enFuse™ system for continuous dopaminergic stimulation, aiming to mitigate motor complications in Parkinson’s patients. Additionally, Serina is exploring further applications of its POZ Platform™ through partnerships and licensing, such as their agreement with Pfizer (NYSE:PFE) for non-exclusive use in drug delivery formulations. Details of this transaction have been filed with the U.S. Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.